Trending Now - Recent Review Questions Efficacy of New Alzheimer’s Treatments

WHO:

Cochrane Collaboration - The review was authored by Francesco Nonino, a neurologist and epidemiologist at the IRCCS Institute of Neurological Sciences of Bologna, Italy, and senior author Edo Richard, Professor of Neurology at Radboud University Medical Centre.

WHAT:

Gizmodo - A new review concluded that anti-amyloid drugs likely provide no "clinically meaningful" effects for people with Alzheimer's disease.

Cochrane Collaboration - The review examined data from 17 clinical trials involving a total of 20,342 participants, focusing on the impact of anti-amyloid drugs on individuals with mild cognitive impairment or mild dementia due to Alzheimer’s disease.

Cochrane Collaboration - The review found that the absolute effects of anti-amyloid drugs on cognitive decline and dementia severity were absent or trivial, falling below established thresholds for the minimum clinically important difference.

Cochrane Collaboration - The review indicated that anti-amyloid drugs likely increase the risk of swelling and bleeding in the brain.

WHERE:

Cochrane Collaboration - The review was conducted by researchers at the IRCCS Institute of Neurological Sciences of Bologna, Italy, and Radboud University Medical Centre.

WHEN:

Cochrane Collaboration - The review was published in 2026.

WHY:

Cochrane Collaboration - The authors concluded that future trials targeting amyloid beta removal are unlikely to provide clear benefits to patients, as the drugs do not translate into meaningful clinical benefits despite successfully removing amyloid proteins from the brain.

Cochrane Collaboration - The review highlighted the need for future research to focus on other mechanisms for treating Alzheimer’s disease due to the absence of correlation between amyloid removal and clinical benefit.

HOW:

Cochrane Collaboration - The review analyzed data from clinical trials that targeted amyloid beta proteins in the brain, which are present in high levels in individuals with Alzheimer’s disease.

(UPDATED April 16, 2026 17:25 UTC)

A new review published by the Cochrane Collaboration has concluded that anti-amyloid drugs likely offer no clinically meaningful effects for people with Alzheimer's disease. Authored by neurologist Francesco Nonino and senior author Edo Richard, the review analyzed data from 17 clinical trials involving over 20,000 participants and found that these drugs do not significantly impact cognitive decline or dementia severity, while potentially increasing the risk of brain swelling and bleeding. The authors emphasized the need for future research to explore other treatment mechanisms, as the removal of amyloid proteins from the brain does not correlate with meaningful clinical benefits for patients.